Research progress of glucagon-like peptide-1 receptor agonists in the treatment of obesity
Obesity is a complex chronic disease.With the improvement of living standards,the amount of overweight and obese people has steadily increased throughout the world and in China.Obesity can lead to a series of health problems,such as car diovascular disease,type 2 diabetes,stroke and even cancer and psychosocial disorders.At present,the treatments of obesity con-tain behavioural change(e.g.,nutrition and exercise)and adjunctive therapies,including pharmacologic and surgical interven-tions.The clinical use of anti-obesity drugs on the market,such as phentermine/topiramate,naltrexone/bupropion,lorcaserin,and orlistat,is limited because of various serious adverse events.Glucagon-likepeptide-1 receptor agonists(GLP-1RAs)are increasingly being appreciated due to its excellent efficacy on weight loss and good safety.This article summarizes the efficacy and safety of Liraglutide and Semaglutide,which have been approved by the food and drug administration for weight loss medication as GLP-1RAs,and GLP-1RA weight loss medication under development at home and abroad,as well as the approval and usage of GLP-1RA weight loss medication in China.This review may serve as a reference for the majority of health workers.
NETL
NSTL
万方数据
